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INTRODUCTION
Photodynamic therapy (PDT) with verteporfin has
been shown to be an effective treatment for choroi-
dal neovascularization (CNV) secondary to age -re-
lated macular degeneration (AMD) (1, 2). Triamci-
nolone acetonide (TA) is a commonly used steroid
in treating ocular inflammation by sub-Tenon’s cap-
sule injection (3). TA has been shown to be an effec-
tive inhibitor of neovascularization, and also known
to be one of the most potent anti-angiogenic drugs
(4). Intravitreal injection of TA as an adjunct to PDT
seems to reduce the growth of CNV and, therefore,
the need for retreatment (5), but it is associated with
side effects of raised intraocular pressure (IOP),
cataract, endophthalmitis and retinal detachment
(6 - 8). The posterior juxtascleral injection of TA
has been reported to have a much lower risk of en-
dophthalmitis and retinal detachment. Indeed, a pre-
vious study has demonstrated the effectiveness of
adjunct posterior juxtascleral TA injection in reduc-
ing the number of retreatments, with a follow-up pe-
riod of 6 months (9).
This study included patients who completed at
least 1 year follow-up after the initial PDT, and in-
vestigated the effect of sub-Tenon’s injection of TA
on CNV, focusing on changes of visual acuity and re-
treatment rates.
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A total of 117 eyes of 117 patients (88 men, 29
women ; mean age 73.8 years) were included in this
study. Between October 2004 and June 2008, 68
eyes of 68 patients underwent PDT with sub-Tenon’s
capsule injection of 20 mg TA (PDT+TA group) and
49 eyes of 49 patients underwent PDT alone (PDT-
only group) at the Department of Ophthalmology
of Tokushima University Hospital. All patients pre-
sented with subfoveal CNV caused by AMD. Be-
tween October 2004 and January 2006, all patients
underwent PDT alone, and thereafter, all patients
underwent adjunctive sub-Tenon’s capsule injection
prior to PDT. All these patients completed 1 year
follow-up. The baseline characteristics of the two
groups were not statistically significantly different.
Institutional approval for the use of TA was obtained,
and informed consent was received from each pa-
tient before treatment.
Baseline characteristics
At baseline, the two groups were comparable for
the type of CNV (PDT-only group 49 eyes, PDT+
TA group 68 eyes). All patients were followed up for
12 months or more. The characteristics of patients
at baseline are summarized in Table 1. There were
no significant differences in gender, age, lesion type,
VA and greatest linear dimension (GLD) between
the two groups.
Follow-up examinations
All patients were scheduled for follow-up every 3
months after the treatment. At each of these exami-
nations, the best-corrected visual acuity (BCVA)
was measured with full subjective refraction using a
Landolt ring chart at 5 m. Fundus photography and
angiography were also performed before treatment
or retreatment, using an Imagenet camera (TRC50
IA, Topcon, Tokyo, Japan). Fundus photographs and
angiograms were obtained at baseline and follow-up
from nearly all subjects, and were evaluated and
graded by one of the authors (TN).
PDT with verteporfin
The treatment protocol of PDT followed the Japa-
nese Age-Related Macular Degeneration Trial (JAT)
study (10). Patients received an infusion of vertepor-
fin (VisudyneTM ; Novartis AG, Basel, Switzerland)
diluted to a volume of 30 ml with 5% dextrose in
water, followed by laser light exposure. A 10-min
infusion of verteporfin was followed 15 min later by
exposure to red diode laser light (689 nm) for ex-
actly 83 s to produce 50 J/cm2. Additional therapy
for eligible patients was given if fluorescein leakage
from the CNV was observed as often as every 3
months during the 12-month follow-up.
Statistical Analysis
Statistical analysis was performed using SPSS
v11.5 software (SPSS, Chicago, IL, USA). Fisher’s
exact tests were used to compare the proportion of
patients between the two groups. Serial changes in
the logarithm of the minimum angle of resolution
(logMAR BCVA) were compared using Wilcoxon
signed ranks test. The mean number of treatments
and lines of BCVA changes in the two groups were
compared using Mann-Whitney U test. We consid-
ered P0.05 as statistically significant.
RESULTS
Number of treatments in both groups
In the PDT+TA group, 48 patients (70.6%) needed
only one treatment, and 20 patients (29.4%) received
two or more treatments. In the PDT-only group, 29
patients (59.2%) received two or more treatments
(Table 2). The PDT+TA group required a lower
mean number of treatments (1.38 versus 1.67, χ2
test P=0.032).
Table 1. Characteristics of patients at baseline
PDT-only group PDT+TA group P value
Gender Men 38 (77.6%) 50 (73.5%) 0.956
Women 11 (22.4%) 18 (26.5%)
Age
(years old) 74.1 73.6 0.988
Diagnosis AMD 39 (79.6%) 45 (66.2%) 0.370
PCV 8 (16.3%) 19 (27.9%)
RAP 2 ( 4.1%) 4 ( 5.9%)
BCVA
(logMAR) 0.87 0.86 0.969
GLD (μm) 3525 3586 0.973
PDT : photodynamic therapy
AMD : age-related macular degeneration
PCV : polypoidal choroidal vasculopathy
RAP : retinal angiomatous proliferation
BCVA : best-corrected visual acuity
logMAR : logarithm of the minimum angle of resolution
GLD : greatest linear dimension
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Change in VA after treatment
BCVA analysis showed statistically no significant
differences between the two groups during the 1-
year follow-up period (Fig. 1).
Complications
Although no side effects related to PDT were
noted, there were side effects related to TA. Medical
therapy was required to control elevated IOP during
the first year in eight (12%) of 68 patients in the
PDT+TA group.
DISCUSSION
Although PDT has been shown to be effective and
has become a major therapeutic option for exudative
AMD, some cases are resistant and require repeated
PDT application. In addition, the possibility that re-
peated PDT may cause retinal damage and result
in progressive thinning of the neurosensory retina
has been investigated in an animal model (11), and
it may be that less PDT has a greater benefit. Our
study confirms that the combination of PDT with TA
significantly reduces the number of retreatments of
PDT.
The most expected complication related to the
use of TA is increased IOP. In the present study, the
rate was lower than that of with intravitreal injection
of TA reported previously (12). This supports the
results of a previous study that sub-Tenon’s capsule
injection of TA is associated with a lower risk of in-
creased IOP than that with intravitreal injection (9).
Other complications of intravitreal injection of TA,
such as conjunctivitis, endophthalmitis and retinal
detachment, did not occur in the present study.
In conclusion, the combination of PDT and sub-
Tenon’s capsule injection of TA was more effective
than PDT alone. The side effects related to this
treatment were tolerable. Future treatments are
likely to include combinations of PDT with corti-
costeroids and anti-VEGF drugs. Prospective, ran-
domized and controlled studies are needed for fur-
ther evaluation of the benefits of combination ther-
apy.
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